Rokit Genomics Signs MOU with Macrogen for ‘Precision Genomic Data Production and Utilization’
Rokit Healthcare’s subsidiary, Rokit Genomics (co-CEOs Tae-Woo Kwon and Yoon-Ki Gil), a company specializing in single-cell analysis, announced on the 22nd that it has signed a memorandum of understanding (MOU) with Macrogen (CEO Chang-Hoon Kim) for the production and utilization of precision genomic data. The signing ceremony was attended by Tae-Woo Kwon, CEO of Rokit Genomics, project manager Ye-Seung Lee, CEO Chang-Hoon Kim of Macrogen, Vice President Eung-Ryong Lee, Director Ji-Hyun Joo, Manager Hyeong-Seok Kim, and other officials.
Founded in 2019, Rokit Genomics provides services based on single-cell transcriptome and gene analysis technology, and its innovative approach is gaining attention in various life sciences and biomedical research. The company particularly supports genomic analysis services and bioinformatics, which are essential for precision medicine.
Through this agreement, the two companies will establish a collaborative framework for:
- Production and provision of precision genomic data
- Joint research and development in the field of precision medicine genomic data utilization
- Production and provision of single-cell genomic data
- Production of precision genomic data in the exosome field
Macrogen will produce high-quality genomic data based on its expertise, while Rokit Genomics plans to use this data to offer customized research services and bioinformatics analysis services to its clients.
Chang-Hoon Kim, CEO of Macrogen, stated, “The construction of medical big data is essential for the realization of personalized treatment and precision medicine, and securing high-quality genomic data is crucial. We hope that the high-level data produced by our company will contribute to advancing the era of precision medicine by being utilized by Rokit Genomics.”
Tae-Woo Kwon, CEO of Rokit Genomics, commented, “This agreement is significant as it allows us to create synergy through collaboration with Macrogen, a leading global genomic analysis company. We will strive to produce stable and up-to-date precision genomic data and provide genomic and bioinformatics analysis services to our customers.”
Rokit Genomics is expanding its business area in single-cell genomic and transcriptomic analysis. In addition to its business using the 10x Genomics platform, the company also offers services using the BD Rhapsody platform, the only one of its kind in Korea. Rokit Genomics has been achieving a steep annual growth rate of over 50% in sales by undertaking numerous national service projects.
